View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 29, 2020updated 12 Jul 2022 11:44am

Janssen halts Phase III LOTUS trial of Stelara in SLE

Janssen Pharmaceutical has decided to suspend the Phase III LOTUS clinical trial of Stelara (ustekinumab) in systemic lupus erythematosus (SLE) patients over efficacy data.

Janssen Pharmaceutical has decided to suspend the Phase III LOTUS clinical trial of Stelara (ustekinumab) in systemic lupus erythematosus (SLE) patients over efficacy data.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Results from a pre-planned interim efficacy analysis showed that the drug lacked efficacy in this indication. The interim safety profile was observed to be consistent with the known profile of the drug, without any new safety signals.

The company informed investigators, study participants, and health authorities regarding its decision to discontinue the LOTUS trial. Janssen noted that the decision will not be applicable to other ustekinumab studies or current indications.

Janssen Research & Development rheumatology disease area leader Alyssa Johnsen said: “Lupus patients are waiting for better treatments, which makes this outcome disappointing.

“Our hope is that by ultimately sharing these data with the scientific community we can help inform lupus research and therefore still have a positive impact on the lives of patients living with SLE.”

Stelara is a human IL-12 and IL-23 antagonist indicated in the US to treat certain patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

The global, randomised, double-blind, placebo-controlled, parallel-group LOTUS trial assessed the drug in 516 patients with active SLE. The primary endpoint was a composite measure of Systemic Lupus Responder Index (SRI-4) response at week 52.

Janssen said that a second Phase III LOTUS-C trial, planned to be performed in China, will not launch in the wake of this decision.

In February this year, Janssen reported interim results from the Phase IIIb STARDUST trial, where the drug led to clinical remission in moderately to severely active Crohn’s disease (CD) patients.

According to the study data, 79% of participants experienced clinical response and 67% were in clinical remission at week 16.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena